17/12/2021 - 15:30

Chimeric wraps up second dose trial of cancer therapy

17/12/2021 - 15:30

Bookmark

Save articles for future reference.

Chimeric Therapeutics has ticked off a new milestone in its battle against an aggressive cancer called “glioblastoma” after the successful completion of a second dose trial following a phase 1 dose escalation study near Los Angeles. The company says all patients dosed as part of the trial have now advanced past the 28 day follow-up period without experiencing any dose limiting toxicities.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options